Research Articles on Tuberculosis from 1940 onwards

Anti-tuberculosis therapy: Urgency for new drugs and integrative approach
Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase
Oncotarget. 2017 Nov 3; 8(54): 91928–91937.
Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Tuberculosis (Edinb). 2016 Mar;97:38-46.
Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis.
Nat Commun. 2014 Jun 30;5:4306.
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
Nat Med. 2013 Sep;19(9):1157-60.
Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summary.
Biomed Res Int. 2015;2015:895453.
Cell-free Mycobacterium tuberculosis DNA test in pleural effusion for tuberculous pleurisy: a diagnostic accuracy study.
Clin Microbiol Infect. 2019 Dec 2. pii: S1198-743X(19)30628-7.
The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.
Sci Rep. 2018 Feb 8;8(1):2625.
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
Nat Med. 2013 Sep;19(9):1157-60.
Isocitrate lyase: a potential target for anti-tubercular drugs.
Recent Pat Inflamm Allergy Drug Discov. 2013 May;7(2):114-23.